Anonymous
Guest
Anonymous
Guest
BLAH BLAH BLAH! Every year same gossip!
BLAH BLAH BLAH! Every year same gossip!
@ least for neuro - psych. keep in mind nat meeting is dec 13 for that div so unless nvs is sending every rep to that meeting (dont think so) an announcement has to be made on dec 3 or sooner. we all shall c.
You're close. REE and CV will be evaluated jointly. We're grouping the pod as a whole and cherry picking who we want to keep. There will be cases of CV reps being let go and REE reps taking the vacant CV spot and vise versa. Time frame still not set. Still might get pushed back to the week of Dec 6th thru 10th. "God bless us all"? Really?
No chance FLM's have a say in this, as one I have heard nothing and during CCI I heard nothing until the day of. Your are all full of B.S. There will be changes, they will be big but as far as details no one knows. Everyone saying they do above even the Directors they do not know.
This has never happened before(managers taking open territories) and I tend to doubt it will start now.
Novartis wouldn't save much money paying managers their same salary as a rep....Won't happen!
The thing that jumps out at me from most of these rumors regarding CV/REE (at least those that are well-written, and there are many of those believe it or not) is that about every one makes the claim that CV/REE is being combined and will go from 5 reps to 3.
That's great except it leaves out an important detail; There are SEVEN reps in a full pod if you count REE and CV. With Specialty Sales (That may be the overlay position for all I know) you have eight.
But to keep it simple--if they are going to three in a pod for General Meds, the number to cut from in a full Pod is not 5 to 3 but 7 to 3.
I have no more idea than anybody else but here is what SHOULD happen.
General Meds: Should have AT MOST three reps. Regardless of geography or managed care. You could probably do it with two depending on how wide the swath is cut for a given territory.
Oncology: I have no idea and dont fucking care. Just ballpark it and say cut them by half.
Psych/Neuro: Fanapt should be sold. The other drugs in Neuro are very unlikely to be worth bothering with as well. I would eliminate this entire division.
Managers: Should have a minimum of 15 reps under them. They dont do anything. I know it, you know it, and they know it. I think they ought to be able to handle approving a few more expense reports. Other than resolving (hopefully) the occasional HR conflict I dont know what else they do. Plus, with more people under them then they wont be in the field with a given rep any more than two or three times a year.
Novartis should consider voluntary layoffs as well. I would say there are a number of people that would happily take a package.
The thing that jumps out at me from most of these rumors regarding CV/REE (at least those that are well-written, and there are many of those believe it or not) is that about every one makes the claim that CV/REE is being combined and will go from 5 reps to 3.
That's great except it leaves out an important detail; There are SEVEN reps in a full pod if you count REE and CV. With Specialty Sales (That may be the overlay position for all I know) you have eight.
But to keep it simple--if they are going to three in a pod for General Meds, the number to cut from in a full Pod is not 5 to 3 but 7 to 3.
I have no more idea than anybody else but here is what SHOULD happen.
General Meds: Should have AT MOST three reps. Regardless of geography or managed care. You could probably do it with two depending on how wide the swath is cut for a given territory.
Oncology: I have no idea and dont fucking care. Just ballpark it and say cut them by half.
Psych/Neuro: Fanapt should be sold. The other drugs in Neuro are very unlikely to be worth bothering with as well. I would eliminate this entire division.
Managers: Should have a minimum of 15 reps under them. They dont do anything. I know it, you know it, and they know it. I think they ought to be able to handle approving a few more expense reports. Other than resolving (hopefully) the occasional HR conflict I dont know what else they do. Plus, with more people under them then they wont be in the field with a given rep any more than two or three times a year.
Novartis should consider voluntary layoffs as well. I would say there are a number of people that would happily take a package.